Neoadjuvant Radiotherapy for HCC Involving Type I PVTT

Guangxi Medical University

Status and phase

Unknown

Phase 3

Phase 2

Conditions

Hepatocellular Carcinoma

Treatments

Procedure: Hepatectomy alone

Radiation: Neoadjuvant radiotherapy

Study type

Interventional

Funder types

Other

Identifiers

NCT04025437

RT-HCC-PVTT

Details and patient eligibility

About

The rate of patients with hepatocellular carcinoma (HCC) involving portal vein tumor thrombus (PVTT) is up to 50% in Guangxi province, China. Some of them will receive hepatic resection, especially those with type I or II PVTT. However, 5-years recurrence rate is up to 75% after surgery. Some retrospective studies found postoperative radiotherapy may reduce the rate of recurrence. Moreover, few retrospective studies also found neoadjuvant radiotherapy (PMID: 27317960) may improve overall survival for HCC patients involving type II/III PVTT. However, the safety and efficacy of neoadjuvant raidotherapy for HCC involving type I PVTT is unknown.

Enrollment

214 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Age 18-75 years;
Patients with resectable primary hepatocellular carcinoma and Cheng's type I portal vein tumor thrombus;
Child-Pugh A or B (7 score) liver function;
With more than 3 months expected survival;
The volume of residual liver more than 30%;
Patients agree to take part in.

Exclusion criteria

Patients with primary hepatocellular carcinoma and Cheng's type II/III/IV portal vein tumor thrombus
Previous history of epigastric radiotherapy
With extrahepatic metastasis
With radiotherapy contraindication;
Pregnant woman or sucking period;
With repture tumor;
With other cancer in previous five years;
With chemothrapy, target therapy or immunosuppressive drugs therapy.